Medicare IVIG Access Enhancement Act

Medicare IVIG Access Enhancement Act

This bill requires the Centers for Medicare & Medicaid Services to establish a five-year demonstration project to evaluate the benefits of providing Medicare coverage and payment for items and services needed for the in-home administration of intravenous immune globulin to treat chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy. Beneficiary participation shall be voluntary.

Bill 117 HR 3808, also known as the Medicare IVIG Access Enhancement Act, is a piece of legislation introduced in the US Congress. The purpose of this bill is to improve access to intravenous immunoglobulin (IVIG) therapy for Medicare beneficiaries.

IVIG therapy is a treatment used for a variety of conditions, including immune deficiencies, autoimmune diseases, and certain neurological disorders. However, there have been challenges in ensuring that Medicare beneficiaries have access to this important therapy.

The Medicare IVIG Access Enhancement Act aims to address these challenges by establishing a demonstration project that would provide Medicare coverage for IVIG therapy in the home setting. This would allow beneficiaries to receive treatment in the comfort of their own homes, rather than having to travel to a healthcare facility. Additionally, the bill includes provisions to improve data collection and reporting on IVIG utilization, as well as measures to ensure that Medicare reimbursement rates for IVIG are adequate to cover the cost of the therapy. Overall, the Medicare IVIG Access Enhancement Act seeks to improve access to IVIG therapy for Medicare beneficiaries, while also addressing issues related to reimbursement and data collection. This legislation has the potential to benefit many individuals who rely on IVIG therapy for their medical conditions.